Patent classifications
A61K40/4217
Administration of Engineered T Cells for Treatment of Cancers in the Central Nervous System
An improved method of treating cancers with engineered T cells is described.
Antigen Binders Specific For IL-23R And Uses Thereof
IL23R overexpression has been described as a common feature of pathogenic inflammatory cells involved in the onset and maintenance of autoimmune diseases and chronic inflammation. The present disclosure relates to a novel antigen binder directed to IL-23R, to compositions that comprise said antigen binder, and to the use of said antigen binder. The present disclosure further relates to fusion proteins comprising said antigen binder, such as, for example, chimeric antigen receptors.
Targeted chimeric antigen receptor modified T cells for treatment of IL13RALPHA2 positive malignancies
Chimeric antigen receptors targeted to IL-13Ra2 are described. The targeting domain is a IL13 variant having increased specificity for IL-13Ra2 relative to IL-13Ra1.
NATURAL KILLER CELL PRODUCTS AND METHODS
The technology relates generally to the field of immunology and relates in part to compositions and methods for growing and storing modified natural killer cells, including for example, conditional chemical regulation of natural killer cell function. The technology further relates to pharmaceutical compositions and treatment of subjects using modified natural killer cells.
IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
Methods and compositions are provided for enhancing anti-tumor effector immune cells with a targeting construct comprising a human IL-13 superkine and/or a human IL-4 superkine. Cytokine or additional co-stimulatory sequences may also be included to enhance the tumoricidal effects of the cells.
DISRUPTION OF ASXL1 IN T CELLS TO ENHANCE IMMUNOTHERAPY
The application relates to modified immune effector cells with enhanced immune cell function, as well as related pharmaceutical compositions. The application further relates to methods for generating the modified immune effector cell and methods for using the modified immune effector cell for treatment of diseases (e.g., adoptive cell therapy).
Recombinant Fc domain - IL2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
The present invention relates to the combination therapy of recombinant Fc domain-IL-2 variant polypeptides with membrane-anchored antigen binding polypeptides in the prevention or treatment of cancer.
BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE/RECEPTOR PAIRS
Engineered orthogonal cytokine receptor/ligand pairs, and methods of use thereof, are provided.